Search clinical trials for: Placebo to Salmeterol Xinafoate / Fluticasone Propionate

Total 393 results

Novartis Pharmaceuticals

Completed

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Asthma

Germany, Spain, United States, Turkey, Canada, Hungary, Slovakia, Italy, Argentina, Czech Republic, France, Peru
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) (INSIST)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Germany, Spain, Turkey, Hungary, Czech Republic, India, Slovakia
Henan University of Traditional Chinese Medicine

Unknown

Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe / Very Severe COPD

Pulmonary Disease, Chronic Obstructive
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Germany, Denmark, Italy, Canada, Czech Republic, Hungary, India, Slovakia, France, Colombia, Finland, Taiwan, Iceland, Peru
Novartis

Completed

Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, France
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Germany, Austria
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV

Pulmonary Disease, Chronic Obstructive

Germany
Imperial College London
European Research Council

Recruiting

Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma (MAELABA)

Asthma

United Kingdom
Orion Corporation, Orion Pharma

Completed

Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)

Asthma

Finland
GlaxoSmithKline

Completed

Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Respiratory Disorders
Northwestern University
GlaxoSmithKline

Withdrawn

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD (AQuOS-COPD)

Chronic Obstructive Pulmonary Disease | Sleep Disorders

United States
Mundipharma Korea Ltd

Terminated

Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol (RECONFFIRM)

Asthma
Queen's University
GlaxoSmithKline

Completed

The Effect of Fluticasone/Salmeterol Combination on Exertional Breathlessness in Patients With Mild COPD

COPD

Canada
National Jewish Health
GlaxoSmithKline

Terminated

Evaluating Genes in Sputum to Measure Drug Response in COPD

Emphysema | Chronic Obstructive Pulmonary Disease (COPD) | Chronic Bronchitis

United States
University of Rostock
GlaxoSmithKline

Completed

Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma

Allergic Asthma

Germany
GlaxoSmithKline

Completed

CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

Asthma

Canada, Bulgaria, Estonia, Spain, Netherlands, Germany, Australia, Austria, Belgium, Finland, Ireland, Latvia, Macedonia, The Former Yugoslav Republic of, New Zealand, United Kingdom
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus

Asthma

Finland
Allergy & Asthma Medical Group & Research Center

Completed

Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID

Asthma | Candidiasis, Oral | Voice Disorders

United States
Eurofarma Laboratorios S.A.

Completed

A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients With Asthma (CAINAS SF)

Asthma

Brazil
Università degli Studi di Brescia

Completed

Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma (FORTINO)

Bronchial Asthma
Boehringer Ingelheim

Completed

Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric)

Asthma
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Colombia, India, Belgium, Argentina, Czech Republic
Allergy and Asthma Center of El Paso
GlaxoSmithKline

Unknown

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

Asthma

United States
National Jewish Health

Completed

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

Asthma

United States
Ache Laboratorios Farmaceuticos S.A.

Withdrawn

Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD

Chronic Obstructive Pulmonary Disease | COPD
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma (CONNECT2)

Asthma

United States
University of Colorado, Denver
United States Department of Defense

Recruiting

Advair HFA in Healthy and HAPE Predisposed Subjects (SWIFTARC)

Altitude Edema

United States
Neutec Ar-Ge San ve Tic A.Ş

Terminated

Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD (COPD)

COPD

Turkey
Leiden University Medical Center
GlaxoSmithKline; Academisch Ziekenhuis Groningen; Netherlands Organisation for... and other collaborators

Terminated

Modification Of Disease Outcome In COPD

Chronic Obstructive Pulmonary Disease

Netherlands
University Medical Center Groningen

Unknown

Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD

COPD

Netherlands
Research in Real-Life Ltd
Mundipharma Research Limited

Completed

Real-world Effectiveness of Combination Therapy in Asthma

Asthma

United Kingdom
Teva Pharmaceuticals USA

Terminated

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

Seasonal Allergic Rhinitis

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma (EXPEDITION)

Asthma

Denmark, United States, Canada, Germany, Sweden, United Kingdom
Research in Real-Life Ltd
Napp Pharmaceuticals Limited

Completed

A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down

Asthma

United Kingdom
Boehringer Ingelheim

Completed

BI 671800 ED in Steroid-naive Asthmatic Patients

Asthma

United States, Australia, Canada, Colombia, Korea, Republic of, Mexico, New Zealand, Peru, Philippines, Taiwan
Pfizer

Completed

A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom
University of Chicago
GlaxoSmithKline

Completed

A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations

Pulmonary Disease, Chronic Obstructive

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Asthma

United States
Mundipharma (China) Pharmaceutical Co. Ltd

Unknown

Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years

Asthma

China
McGill University Health Centre/Research Institute...
GlaxoSmithKline

Completed

Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation

Chronic Obstructive Pulmonary Disease | COPD

Canada
GlaxoSmithKline

Completed

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease (ESWT)

Pulmonary Disease, Chronic Obstructive

Canada, United States
GlaxoSmithKline

Completed

Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Professor Warren Lenney

Completed

Management of Asthma in School-age Children on Therapy (MASCOT)

Asthma
Organon and Co

Completed

Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)

Asthma
Imperial College London

Completed

Pharmacokinetics of Inhaled Monodisperse Fluticasone Propionate

Healthy | Asthma

United Kingdom
Brigham and Women's Hospital

Completed

Replication of the INSPIRE Trial in Healthcare Claims Data

Chronic Obstructive Pulmonary Disease

United States
Hull University Teaching Hospitals NHS Trust

Completed

Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United Kingdom

3

Subscribe